CL
Still on the bull side
JPMorgan didn’t hit the brakes on Colgate-Palmolive — it just eased off the gas a little. The bank maintained its Overweight rating on CL while cutting its price target from $97 to $95, a modest 2.06% trim.
For investors, that’s the classic “we still like the story, just not quite as much as before” move. The stock was last around $85.91, so even the lower target still leaves some upside on the table. Not moonshot territory, sure, but enough to keep the bulls from fully wandering off.
Why you should care
Analyst calls don’t move the whole business, but they can nudge sentiment — especially for a defensive name like Colgate, where investors are often hunting for stability in a choppy market. An Overweight rating tells you JPMorgan still thinks CL can outperform, even if it’s now expecting a slightly less generous finish line.
The subtext
The article also flags heavy insider selling over the past three months, with about $25.1 million in shares sold. That doesn’t automatically mean trouble — insiders sell for all kinds of reasons, including the deeply unsexy ones like taxes and diversification — but it can make investors squint a little harder at the stock.
Big picture: JPMorgan’s note is basically a shrug with a smile. The firm still likes Colgate, just not enough to keep the old target intact. In a market obsessed with big drama, this is more “minor haircut” than “bad breakup.”